Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.

Cancer cell | 2017

Cyclins and cyclin-dependent kinases (CDKs) are hyperactivated in numerous human tumors. To identify means of interfering with cyclins/CDKs, we performed nine genome-wide screens for human microRNAs (miRNAs) directly regulating cell-cycle proteins. We uncovered a distinct class of miRNAs that target nearly all cyclins/CDKs, which are very effective in inhibiting cancer cell proliferation. By profiling the response of over 120 human cancer cell lines, we derived an expression-based algorithm that can predict the response of tumors to cell-cycle-targeting miRNAs. Using systemic administration of nanoparticle-formulated miRNAs, we inhibited tumor progression in seven mouse xenograft models, including three treatment-refractory patient-derived tumors, without affecting normal tissues. Our results highlight the utility of using cell-cycle-targeting miRNAs for treatment of refractory cancer types.

Pubmed ID: 28399412 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


New England Biolabs (tool)

RRID:SCR_013517

An Antibody supplier

View all literature mentions

Anti-β-Actin Antibody (antibody)

RRID:AB_476744

This monoclonal targets slightly modified β-cytoplasmic actin N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to KLH

View all literature mentions

Cdk6 antibody (antibody)

RRID:AB_940952

This monoclonal targets Cdk6 antibody

View all literature mentions

Cdk4 (C-22) (antibody)

RRID:AB_631219

This polyclonal targets CDK4

View all literature mentions

Cdk2 (D-12) (antibody)

RRID:AB_627238

This monoclonal targets Cdk2 (D-12)

View all literature mentions

CDK1 antibody [EPR165] (antibody)

RRID:AB_11155333

This monoclonal targets CDK1 antibody [EPR165]

View all literature mentions

Cyclin B1 antibody (antibody)

RRID:AB_2072263

This polyclonal targets Cyclin B1

View all literature mentions

NEW Anti-Cyclin A2, clone 17B8.2 (antibody)

RRID:AB_11204171

This monoclonal targets NEW Cyclin A2 clone 17B8.2

View all literature mentions

Anti-Cyclin E2, clone EP454Y, rabbit monoclonal (antibody)

RRID:AB_1586967

This monoclonal targets Cyclin E2 clone EP454Y rabbit monoclonal

View all literature mentions

cyclin E (HE12) (antibody)

RRID:AB_627357

This monoclonal targets cyclin E (HE12)

View all literature mentions

cyclin D3 (C-16) (antibody)

RRID:AB_2259653

This unknown targets Raised against peptide corresponding to an AA sequence at the C-terminus of human origin (Identical to corresponding sequence in mouse)

View all literature mentions

Anti-Cyclin D1, clone EPR2241(IHC)-32 Rabbit Monoclonal (antibody)

RRID:AB_10615820

This monoclonal targets Cyclin D1 clone EPR2241(IHC)-32 Rabbit

View all literature mentions

The Cancer Genome Atlas (biomaterial supply resource)

RRID:SCR_003193

Project exploring the spectrum of genomic changes involved in more than 20 types of human cancer that provides a platform for researchers to search, download, and analyze data sets generated. As a pilot project it confirmed that an atlas of changes could be created for specific cancer types. It also showed that a national network of research and technology teams working on distinct but related projects could pool the results of their efforts, create an economy of scale and develop an infrastructure for making the data publicly accessible. Its success committed resources to collect and characterize more than 20 additional tumor types. Components of the TCGA Research Network: * Biospecimen Core Resource (BCR); Tissue samples are carefully cataloged, processed, checked for quality and stored, complete with important medical information about the patient. * Genome Characterization Centers (GCCs); Several technologies will be used to analyze genomic changes involved in cancer. The genomic changes that are identified will be further studied by the Genome Sequencing Centers. * Genome Sequencing Centers (GSCs); High-throughput Genome Sequencing Centers will identify the changes in DNA sequences that are associated with specific types of cancer. * Proteome Characterization Centers (PCCs); The centers, a component of NCI's Clinical Proteomic Tumor Analysis Consortium, will ascertain and analyze the total proteomic content of a subset of TCGA samples. * Data Coordinating Center (DCC); The information that is generated by TCGA will be centrally managed at the DCC and entered into the TCGA Data Portal and Cancer Genomics Hub as it becomes available. Centralization of data facilitates data transfer between the network and the research community, and makes data analysis more efficient. The DCC manages the TCGA Data Portal. * Cancer Genomics Hub (CGHub); Lower level sequence data will be deposited into a secure repository. This database stores cancer genome sequences and alignments. * Genome Data Analysis Centers (GDACs) - Immense amounts of data from array and second-generation sequencing technologies must be integrated across thousands of samples. These centers will provide novel informatics tools to the entire research community to facilitate broader use of TCGA data. TCGA is actively developing a network of collaborators who are able to provide samples that are collected retrospectively (tissues that had already been collected and stored) or prospectively (tissues that will be collected in the future).

View all literature mentions

Cancer Cell Line Encyclopedia (data or information resource)

RRID:SCR_013836

A collaborative project between the Broad Institute and the Novartis Institutes for Biomedical Research and its Genomics Institute of the Novartis Research Foundation, with the goal of conducting a detailed genetic and pharmacologic characterization of a large panel of human cancer models. The CCLE also works to develop integrated computational analyses that link distinct pharmacologic vulnerabilities to genomic patterns and to translate cell line integrative genomics into cancer patient stratification. The CCLE provides public access to genomic data, analysis and visualization for about 1000 cell lines.

View all literature mentions

Ensembl (software resource)

RRID:SCR_002344

Collection of genome databases for vertebrates and other eukaryotic species with DNA and protein sequence search capabilities. Used to automatically annotate genome, integrate this annotation with other available biological data and make data publicly available via web. Ensembl tools include BLAST, BLAT, BioMart and the Variant Effect Predictor (VEP) for all supported species.

View all literature mentions

miRDB (data analysis service)

RRID:SCR_010848

An online database for miRNA target prediction and functional annotations.

View all literature mentions

miRNA (data or information resource)

RRID:SCR_010849

Data set of 2003 and 2005 miRNA-Target predictions for Drosophila miRNAs.

View all literature mentions

TargetScan (software resource)

RRID:SCR_010845

Web tool to predict biological targets of miRNAs by searching for presence of conserved 8mer, 7mer and 6mer sites that match seed region of each miRNA. Nonconserved sites are also predicted and sites with mismatches in seed region that are compensated by conserved 3' pairing. Used to search for predicted microRNA targets in mammals.

View all literature mentions